Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 16/20 | 0.73 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.73 |
| ▸ | TSHR | P16473 | 3/20 | 0.73 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.73 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.73 |
| ▸ | HTR2A | P28223 | 2/20 | 0.73 |
| ▸ | HTR2C | P28335 | 2/20 | 0.73 |
| ▸ | HRH1 | P35367 | 2/20 | 0.73 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.73 |
| ▸ | DRD3 | P35462 | 2/20 | 0.73 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.73 |
| ▸ | HTR2B | P41595 | 2/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.73 |
| ▸ | KLF10 | Q13118 | 2/20 | 0.73 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5162653 | 1.00 | SLC6A4 (0.73) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2615186 | 0.87 | SLC6A4 (0.81) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL21222911 | 0.86 | SLC6A4 (0.62) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL2209541 | 0.85 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL29440242 | 0.85 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL5783906 | 0.85 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL341802 | 0.85 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL34268 | 0.85 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL12047445 | 0.85 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5161697 | 0.84 | SLC6A4 (0.50) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1790337-A2 | Methods and compounds for treating depression and other disorders | NPS PHARMACEUTICALS, INC. (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1096926-B1 | METHODS AND COMPOUNDS FOR TREATING DEPRESSION | NPS PHARMA INC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20040039014-A1 | Methods and compounds for treating depression and other disorders | NPS PHARMACEUTICALS, INC. | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039014-A1 | Methods and compounds for treating depression and other disorders | GRIN1, GRIN2C, GRIN3B | SLC6A4 24/4885SLC6A2 89/4885CYP1A2 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.